Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 25, 2017 07:55 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5(TM) Topical Gel

FRAMINGHAM, MA--(Marketwired - Jul 25, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...
June 06, 2017 12:25 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017

FRAMINGHAM, MA--(Marketwired - Jun 6, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...
May 22, 2017 07:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017

FRAMINGHAM, MA--(Marketwired - May 22, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be...
March 06, 2017 07:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Update at the 29th Annual Roth Conference on Monday, March 13, 2017

FRAMINGHAM, MA--(Marketwired - Mar 6, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and...
February 27, 2017 08:18 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Update at the Maxim Group - Haitong Securities Healthcare Investor and Partnering Conference

FRAMINGHAM, MA--(Marketwired - Feb 27, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic...
February 21, 2017 09:08 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics, Inc. $6.1 Million Registered Direct Offering

FRAMINGHAM, MA--(Marketwired - Feb 21, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a developer of innovative materials as hemostatic and wound care devices, today...
February 16, 2017 11:05 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Provides Corporate Milestone Update, Including Anticipated Filing of 510(k) for AC5(TM)

FRAMINGHAM, MA--(Marketwired - Feb 16, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH), developer of innovative materials as hemostatic and wound care devices,...
February 08, 2017 07:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Updates at Two Conferences in New York, February 2017

FRAMINGHAM, MA--(Marketwired - Feb 8, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and...
February 02, 2017 07:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces Issuance of Method-of-Use Patent Covering Self-Assembling Peptidomimetics

FRAMINGHAM, MA--(Marketwired - Feb 2, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, announced...
January 23, 2017 09:44 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Present at Noble Financial Capital Markets' Thirteenth Annual Equity Conference

FRAMINGHAM, MA--(Marketwired - Jan 23, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5™ devices for use in...

Next Page keyboard_arrow_right